Drug Trial Radar · NCT02655315
Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
372
Actual
Start
Feb 9, 2016
Primary completion
Sep 22, 2020
Study completion Sep 22, 2020
Sponsor
- Lead sponsor
- University Hospital, LilleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- European Commission; ApoPharma
- First posted
- Jan 14, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the effect of iron chelation as a therapeutic strategy to slow the progression of Parkinson's disease. Half of participants will receive the deferiprone to 15 mg / kg twice daily morning and evening (30mg / kg per day), while the other half will receive a placebo. The treatment lasts nine months.
Conditions
- Parkinson Disease
Interventions
DeferiproneDrug
15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
PlaceboDrug
the placebo twice daily morning and evening. The treatment lasts nine months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Global effect (symptomatic and disease modifying effects) on motor and non motor handicapTime frame: at 36 weeks
Locations
25 sites in 8 countries. Site status is shown where the registry gives one.
Medizinische Universitat Innsbruck
Innsbruck, Austria
Charles University
Prague, Czechia
Univerzita Karlova V Praze
Prague, Czechia
CHU Pellegrin
Bordeaux, France
Hôpital Wertheimer
Bron, France
Hôpital Montpied
Clermont-Ferrand, France
Hôpital Salengro, CHRU
Lille, France
CHU la TIMONE
Marseille, France
AP-HP, Hôpital Pitié-Salpêtrière
Paris, France
CHU de Strasbourg, Hôpital de Hautepierre
Strasbourg, France
Chu Purpan
Toulouse, France
University Hospital, Saarland University
Homburg, Germany
Christian-albrechts universität zu kiel
Kiel, Germany
Klinik und Poliklinik für Neurologie der Universitätsmedizin Rostock
Rostock, Germany
Acadamic central center, Amsterdam
Amsterdam, Netherlands
Radboud university medical center
Nijmegen, Netherlands
Centro Hospitalar e universitario de Coimbra
Coimbra, Portugal
Centro Hospitalar do Alto Ave
Guimarães, Portugal
Centro Hospitalar Lisboa Norte
Lisbon, Portugal
Hospital Clinic Universitari de Barcelona
Barcelona, Spain
Hospital de Bellvitge
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Cambridge University Hospital
Cambridge, United Kingdom
University of Glasgow
Glasgow, United Kingdom
Newcastle University
Newcastle, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.